Veraxa Biotech to Seek Partners with BiTAC-ADC After In Vitro Tumor Spheroid Success
VRXA•Veraxa Biotech’s BiTAC-ADC platform achieved dose-dependent cytotoxicity in vitro, selectively killing 3D breast cancer cell spheroids while sparing healthy cells. The company will present these differentiated preclinical data and initiate partnering discussions for its BiTAC-ADC and BiTAC-TCE technologies at the BIO International Convention, June 22-25, 2026.
1. In Vitro Proof-of-Concept Data
Veraxa’s BiTAC-ADC platform delivered dose-dependent cytotoxicity in in vitro studies, demonstrating selective killing of 3D breast cancer spheroids while sparing healthy cells. Single-component precursors were non-toxic, indicating the safety-by-design of the dual-antibody prodrug activation mechanism.
2. Mechanism and Differentiation
The BiTAC strategy uses two antibodies to deliver a systemically inactive prodrug and a proactivator to distinct tumor antigens, triggering tumor-restricted activation upon co-localization. This approach enables use of potent payloads with reduced off-tumor toxicity compared to conventional ADCs.
3. Partnering Discussions at BIO Convention
Veraxa will present detailed BiTAC-ADC and BiTAC-TCE data at the BIO International Convention, June 22-25, 2026 in San Diego. The company is engaging potential collaborators to apply its dual-precursor platform across multiple solid tumor indications.
